BMS-247550 in Treating Patients With Metastatic Colorectal Cancer

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
University of Alabama at Birmingham
Study ID
NCT00033306
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ixabepilone — DRUG
  • Fluoropyrimidine — DRUG
  • Irinotecan — DRUG

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BMS-247550 in treating patients who have metastatic colorectal cancer.

Key Dates

Start date
Feb 28, 2002
Status verified
Aug 2013
Primary completion
Jul 31, 2005
Completion
Jul 31, 2005

Study Design

Enrollment
2 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: BMS-247550

Primary Outcome Measure

Determine the clinical activity of BMS-247550, as measured by the tumor response rate, in patients with metastatic colorectal cancer previously treated with a fluoropyrimidine and irinotecan. [ Time Frame: baseline to survival ]

Locations (2)

FacilityCityStateZIPSite coordinators
University of Alabama at Birmingham Comprehensive Cancer CenterBirminghamAlabama35294-3300-
Georgia Cancer SpecialistsAtlantaGeorgia30342-

Find similar trials in Birmingham, AL

By condition
Colorectal cancer
By specialty
OncologyGI oncology
By research site
University of Alabama at Birmingham Comprehensive Cancer Center· Birmingham, ALGeorgia Cancer Specialists· Atlanta, GA

Related Studies